AU2021300188A1 - Formulations for promoting hydration and methods of use thereof - Google Patents

Formulations for promoting hydration and methods of use thereof Download PDF

Info

Publication number
AU2021300188A1
AU2021300188A1 AU2021300188A AU2021300188A AU2021300188A1 AU 2021300188 A1 AU2021300188 A1 AU 2021300188A1 AU 2021300188 A AU2021300188 A AU 2021300188A AU 2021300188 A AU2021300188 A AU 2021300188A AU 2021300188 A1 AU2021300188 A1 AU 2021300188A1
Authority
AU
Australia
Prior art keywords
aspartic acid
ranges
molar ratio
serine
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021300188A
Other languages
English (en)
Inventor
Samuel Cheuvront
Stephen GATTO
Astrid GROSCHE
Robert KENEFICK
Shanshan LIN
Sadasivan Vidyasagar
Xiaodong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Amilyfe LLC
Original Assignee
University of Florida Research Foundation Inc
Amilyfe LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc, Amilyfe LLC filed Critical University of Florida Research Foundation Inc
Publication of AU2021300188A1 publication Critical patent/AU2021300188A1/en
Assigned to UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, AMILYFE, LLC reassignment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Amend patent request/document other than specification (104) Assignors: ENTRINSIC, LLC., UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2021300188A 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof Pending AU2021300188A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047300P 2020-07-02 2020-07-02
US63/047,300 2020-07-02
PCT/US2021/040090 WO2022006397A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2021300188A1 true AU2021300188A1 (en) 2023-02-02

Family

ID=79314908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021300188A Pending AU2021300188A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Country Status (11)

Country Link
US (2) US12357600B2 (https=)
EP (1) EP4175662A4 (https=)
JP (1) JP2023533617A (https=)
KR (1) KR20230047371A (https=)
CN (1) CN116194136A (https=)
AU (1) AU2021300188A1 (https=)
BR (1) BR112022027124A2 (https=)
CA (1) CA3184691A1 (https=)
IL (1) IL299488A (https=)
MX (1) MX2023000004A (https=)
WO (1) WO2022006397A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
CN102170876B (zh) * 2008-10-06 2013-12-04 株式会社明治 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂
KR101758424B1 (ko) * 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
HK1204290A1 (en) * 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
EP3459540A1 (en) * 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
EP3522882A4 (en) * 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND USES THEREOF
CN109218470B (zh) * 2017-07-05 2021-08-24 中兴通讯股份有限公司 移动终端及其控制方法
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
US12357600B2 (en) 2025-07-15
US20230149335A1 (en) 2023-05-18
US20250367154A1 (en) 2025-12-04
MX2023000004A (es) 2023-03-06
CA3184691A1 (en) 2022-12-30
WO2022006397A1 (en) 2022-01-06
KR20230047371A (ko) 2023-04-07
EP4175662A1 (en) 2023-05-10
JP2023533617A (ja) 2023-08-03
CN116194136A (zh) 2023-05-30
BR112022027124A2 (pt) 2023-03-07
EP4175662A4 (en) 2024-07-17
IL299488A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
Aruga et al. Chronic metabolic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney
Ambuhl et al. Chronic metabolic acidosis increases NHE3 protein abundance in rat kidney
CN103153298B (zh) 用于改善胃肠功能的材料和方法
CN102512408B (zh) 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
JP4549847B2 (ja) 肝炎の治療方法
Takeda et al. The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops
US20250367154A1 (en) Formulations for promoting hydration and methods of use thereof
Chen et al. Glutamine‐supplemented parenteral nutrition improves gut mucosa integrity and function in endotoxemic rats
JP2000506895A (ja) 下痢治療におけるクロトリマゾールおよび関連化合物の使用
Benzer et al. Case 40-2013: a 36-year-old man with agitation and paranoia
CN115916185B (zh) 用于治疗腹泻的制剂和方法
Arruda et al. Distal renal tubular acidosis: molecular and clinical aspects
US20250312297A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
Donawick Metabolic Management of the Horse with Acute Abdominal Crisis
CN102596872A (zh) 赤藓醇用于预防或治疗高血压的用途
Hayat et al. Enhanced Autophagy Activity in Laminar Tissue Damage of Acute Laminitis in Dairy Cows Induced by Oligofructose Overload
Musio et al. Effect of glycine on cisplatin nephrotoxicity and heat-shock protein 70 expression in the rat kidney
US20250302777A1 (en) Methods for treating gastroparesis
CN119924421A (zh) L-半胱氨酸作为猫科动物aim蛋白激活剂的用途以及用于猫科动物改善肾功能的用途
Doble et al. Luminal osmolarity downregulates gene expression of Na+/H+ exchanger (NHE3) in rat colon mucosa
Doble et al. Luminal regulation of Na+/H+ exchanger gene expression in rat ileal mucosa
CN120188851A (zh) 维生素b1作为猫科动物aim蛋白激活剂的用途以及用于猫科动物改善肾功能的用途
WO2022019235A1 (ja) 腎障害の抑制におけるビタミンｂ１２の利用
Kabadi et al. Goiter: A Review of Pathophysiology and Management
BERLIN et al. CLOSEST APPROACH TO THE IDEAL ANABOLlC AGENT

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AMILYFE, LLC

Free format text: FORMER NAME(S): UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED; ENTRINSIC, LLC.

Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Free format text: FORMER NAME(S): UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED; ENTRINSIC, LLC.